Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Wednesday morning,Benzinga reports. They currently have a $46.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on AVXL. HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Friday, August 22nd. Wall Street Zen downgraded shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 23rd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $44.00.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $8.88 on Wednesday. The company has a market cap of $762.70 million, a PE ratio of -15.58 and a beta of 0.83. Anavex Life Sciences has a 12 month low of $4.93 and a 12 month high of $14.44. The company has a 50-day simple moving average of $10.52 and a 200-day simple moving average of $9.30.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Anavex Life Sciences by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock valued at $42,061,000 after buying an additional 221,802 shares in the last quarter. Private Advisor Group LLC lifted its position in Anavex Life Sciences by 617.5% during the first quarter. Private Advisor Group LLC now owns 214,725 shares of the biotechnology company’s stock valued at $1,842,000 after buying an additional 184,800 shares in the last quarter. Swiss National Bank acquired a new position in Anavex Life Sciences during the first quarter valued at approximately $1,411,000. Arizona State Retirement System acquired a new position in Anavex Life Sciences during the first quarter valued at approximately $208,000. Finally, Cambridge Investment Research Advisors Inc. lifted its position in Anavex Life Sciences by 197.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company’s stock valued at $2,129,000 after buying an additional 164,792 shares in the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.